1.51
0.03 (2.03%)
| Penutupan Terdahulu | 1.48 |
| Buka | 1.43 |
| Jumlah Dagangan | 27,443 |
| Purata Dagangan (3B) | 184,079 |
| Modal Pasaran | 10,823,259 |
| Harga / Pendapatan (P/E TTM) | 4.19 |
| Harga / Buku (P/B) | 1.51 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -1.12 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 64.46% |
| Nisbah Semasa (MRQ) | 2.12 |
| Aliran Tunai Operasi (OCF TTM) | -22.99 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -15.51 M |
| Pulangan Atas Aset (ROA TTM) | -111.74% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Calidi Biotherapeutics, Inc. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 1.13 |
|
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is based in San Diego, California. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 5.43% |
| % Dimiliki oleh Institusi | 15.88% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Rs Crum Inc. | 30 Sep 2025 | 15,256 |
| Grassi Investment Management | 30 Jun 2025 | 833 |
| Barrett & Company, Inc. | 30 Sep 2025 | 292 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |